Home › Companies › Cytokinetics, Incorporated › 2025-2026
Compiled from SEC Form N-PX filings and Cytokinetics, Incorporated’s Form 8-K, filed 2026-05-27 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Cytokinetics, Incorporated in the interactive database Compare manager voting policies
These tallies are Cytokinetics, Incorporated’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-27 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Edward M. Kaye, M.D. | 104,633,356 | -- | -- | 3,234,862 | 8,257,512 | Majority: yes |
| Elect Director: Wendell Wierenga, Ph.D. | 85,427,010 | -- | -- | 22,441,208 | 8,257,512 | Majority: yes |
| Elect Director: Nancy J. Wysenski | 104,820,911 | -- | -- | 3,047,307 | 8,257,512 | Majority: yes |
| Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2015 Employee Stock Purchase Plan by 1,000,000 | 107,254,415 | 261,354 | 352,449 | -- | 8,257,512 | Majority: yes |
| Proposal 3: Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026 The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & You | 115,468,025 | 269,258 | 388,447 | -- | 0 | Majority: yes |
| Proposal 4: Advisory Vote on Executive Compensation The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company's Proxy Statement for the 2026 Annual Meeting of Stockholders | 104,005,531 | 3,018,095 | 844,592 | -- | 8,257,512 | Majority: yes |
Source: Cytokinetics, Incorporated, Form 8-K, filed with the SEC on 2026-05-27 — read the filing on EDGAR.
Each item below shows how the 414 asset managers that disclosed a Cytokinetics, Incorporated vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 9 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Cytokinetics, Incorporated’s own tally for this item (“Proposal 4: Advisory Vote on Executive Compensation The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company's Proxy Statement for the 2026 Annual Mee”): 104,005,531 for, 3,018,095 against, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 124,432,565 outstanding shares: 84% for, 2% against (86% of the company cast a for/against vote).
The 411 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 30,484,440 | 0 | 0 | 0 | For |
| Fidelity | 21,409,763 | 0 | 0 | 0 | For |
| Vanguard | 17,287,183 | 4 | 1 | 0 | For |
| BlackRock | 12,054,769 | 1,007 | 213 | 0 | For |
| Wellington | 6,706,576 | 0 | 0 | 0 | For |
| State Street | 4,883,109 | 0 | 0 | 0 | For |
| Capital Group | 3,938,577 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 3,087,854 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,795,792 | 0 | 0 | 0 | For |
| Charles Schwab | 2,778,478 | 0 | 0 | 0 | For |
| Jackson National | 1,802,690 | 85,693 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 1,746,254 | 0 | 0 | 0 | For |
| Federated Hermes | 1,397,052 | 622 | 0 | 0 | For |
| Northern Trust | 1,189,225 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 1,159,879 | 0 | 0 | 0 | For |
| Voya | 1,009,579 | 0 | 0 | 0 | For |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 855,671 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 786,678 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 770,999 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 714,344 | 0 | 0 | Against |
| American Century | 710,697 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 702,646 | 0 | 0 | 0 | For |
| Goldman Sachs | 697,828 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 696,571 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 682,881 | 0 | 0 | 0 | For |
Showing the 25 largest of 411 asset managers. See all 411 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Cytokinetics, Incorporated’s own tally for this item (“Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2015 Em”): 107,254,415 for, 261,354 against, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 124,432,565 outstanding shares: 86% for, 0.3% against (86% of the company cast a for/against vote).
The 115 asset managers below cast 99.9% of the shares they voted on this item FOR (65,793,645 for, 28,784 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 16,283,021 | 0 | 1 | 0 | For |
| T. Rowe Price | 12,088,585 | 0 | 0 | 0 | For |
| Fidelity | 11,423,245 | 0 | 0 | 0 | For |
| BlackRock | 8,039,816 | 0 | 0 | 0 | For |
| Capital Group | 2,351,843 | 0 | 0 | 0 | For |
| State Street | 1,952,001 | 0 | 0 | 0 | For |
| Jackson National | 1,888,383 | 0 | 0 | 0 | For |
| Charles Schwab | 1,381,375 | 0 | 0 | 0 | For |
| Federated Hermes | 698,221 | 0 | 0 | 0 | For |
| Principal | 546,147 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 484,644 | 0 | 0 | 0 | For |
| Voya | 472,562 | 0 | 0 | 0 | For |
| JPMorgan | 469,912 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 408,465 | 0 | 0 | 0 | For |
| Equitable | 405,573 | 0 | 0 | 0 | For |
| John Hancock | 366,389 | 0 | 0 | 0 | For |
| American Century | 339,530 | 0 | 0 | 0 | For |
| MFS | 305,698 | 0 | 0 | 0 | For |
| Goldman Sachs | 281,731 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 256,383 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 255,713 | 0 | 0 | 0 | For |
| TIAA | 241,442 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 228,990 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 225,640 | 0 | 0 | 0 | For |
| Brighthouse | 195,741 | 28,784 | 0 | 0 | For |
Showing the 25 largest of 115 asset managers. See all 115 in the interactive database.
Combines 4 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Cytokinetics, Incorporated’s own tally for this item (“Elect Director: Edward M. Kaye, M.D.”): 104,633,356 for, 3,234,862 withheld, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 124,432,565 outstanding shares: 84% for, 3% withheld (87% of the company cast a for/withheld vote).
The 109 asset managers below cast 100% of the shares they voted on this item FOR (63,947,327 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 16,283,015 | 0 | 7 | 0 | For |
| T. Rowe Price | 10,923,847 | 0 | 1,164,738 | 0 | For |
| Fidelity | 11,423,245 | 0 | 0 | 0 | For |
| BlackRock | 8,039,816 | 0 | 0 | 0 | For |
| Capital Group | 2,351,843 | 0 | 0 | 0 | For |
| State Street | 1,952,001 | 0 | 0 | 0 | For |
| Jackson National | 1,888,383 | 0 | 0 | 0 | For |
| Charles Schwab | 1,381,375 | 0 | 0 | 0 | For |
| Federated Hermes | 698,221 | 0 | 0 | 0 | For |
| Principal | 497,274 | 0 | 48,873 | 0 | For |
| MUTUAL FUND SERIES TRUST | 484,644 | 0 | 0 | 0 | For |
| Voya | 472,562 | 0 | 0 | 0 | For |
| JPMorgan | 469,912 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 408,465 | 0 | 0 | 0 | For |
| Equitable | 205,840 | 0 | 199,733 | 0 | For |
| John Hancock | 351,649 | 0 | 14,740 | 0 | For |
| American Century | 339,530 | 0 | 0 | 0 | For |
| MFS | 305,698 | 0 | 0 | 0 | For |
| Goldman Sachs | 281,731 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 256,383 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 255,713 | 0 | 0 | 0 | For |
| TIAA | 241,442 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 228,990 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 225,640 | 0 | 0 | 0 | For |
| Brighthouse | 176,250 | 0 | 48,275 | 0 | For |
Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.
Combines 4 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Cytokinetics, Incorporated’s own tally for this item (“Elect Director: Nancy J. Wysenski”): 104,820,911 for, 3,047,307 withheld, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 124,432,565 outstanding shares: 84% for, 2% withheld (87% of the company cast a for/withheld vote).
The 109 asset managers below cast 100% of the shares they voted on this item FOR (63,958,674 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 16,283,016 | 0 | 6 | 0 | For |
| T. Rowe Price | 10,923,847 | 0 | 1,164,738 | 0 | For |
| Fidelity | 11,423,245 | 0 | 0 | 0 | For |
| BlackRock | 8,039,816 | 0 | 0 | 0 | For |
| Capital Group | 2,351,843 | 0 | 0 | 0 | For |
| State Street | 1,952,001 | 0 | 0 | 0 | For |
| Jackson National | 1,888,383 | 0 | 0 | 0 | For |
| Charles Schwab | 1,381,375 | 0 | 0 | 0 | For |
| Federated Hermes | 698,221 | 0 | 0 | 0 | For |
| Principal | 497,274 | 0 | 48,873 | 0 | For |
| MUTUAL FUND SERIES TRUST | 484,644 | 0 | 0 | 0 | For |
| Voya | 472,562 | 0 | 0 | 0 | For |
| JPMorgan | 469,912 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 408,465 | 0 | 0 | 0 | For |
| Equitable | 205,840 | 0 | 199,733 | 0 | For |
| John Hancock | 351,649 | 0 | 14,740 | 0 | For |
| American Century | 339,530 | 0 | 0 | 0 | For |
| MFS | 305,698 | 0 | 0 | 0 | For |
| Goldman Sachs | 281,731 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 256,383 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 255,713 | 0 | 0 | 0 | For |
| TIAA | 241,442 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 228,990 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 225,640 | 0 | 0 | 0 | For |
| Brighthouse | 176,250 | 0 | 48,275 | 0 | For |
Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Cytokinetics, Incorporated’s own tally for this item (“Elect Director: Wendell Wierenga, Ph.D.”): 85,427,010 for, 22,441,208 withheld, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 124,432,565 outstanding shares: 69% for, 18% withheld (87% of the company cast a for/withheld vote).
The 109 asset managers below cast 100% of the shares they voted on this item FOR (50,207,324 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 16,276,543 | 0 | 6,479 | 0 | For |
| T. Rowe Price | 0 | 0 | 12,088,585 | 0 | Abstain |
| Fidelity | 11,423,245 | 0 | 0 | 0 | For |
| BlackRock | 8,039,816 | 0 | 0 | 0 | For |
| Capital Group | 2,351,843 | 0 | 0 | 0 | For |
| State Street | 1,951,905 | 0 | 96 | 0 | For |
| Jackson National | 315,606 | 0 | 1,572,777 | 0 | Abstain |
| Charles Schwab | 1,381,375 | 0 | 0 | 0 | For |
| Federated Hermes | 698,221 | 0 | 0 | 0 | For |
| Principal | 497,274 | 0 | 48,873 | 0 | For |
| MUTUAL FUND SERIES TRUST | 484,644 | 0 | 0 | 0 | For |
| Voya | 472,562 | 0 | 0 | 0 | For |
| JPMorgan | 469,912 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 26,151 | 0 | 382,314 | 0 | Abstain |
| Equitable | 205,840 | 0 | 199,733 | 0 | For |
| John Hancock | 198,543 | 0 | 167,846 | 0 | For |
| American Century | 339,530 | 0 | 0 | 0 | For |
| MFS | 305,698 | 0 | 0 | 0 | For |
| Goldman Sachs | 281,731 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 256,383 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 255,713 | 0 | 0 | 0 | For |
| TIAA | 241,442 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 228,990 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 225,640 | 0 | 0 | 0 | For |
| Brighthouse | 166,249 | 0 | 58,276 | 0 | For |
Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Cytokinetics, Incorporated’s own tally for this item (“Proposal 3: Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026 The stockholders ratified the selection by the Audit Committee ”): 115,468,025 for, 269,258 against, per its Form 8-K filed 2026-05-27 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 124,432,565 outstanding shares: 93% for, 0.3% against (93% of the company cast a for/against vote).
The 109 asset managers below cast 99.9% of the shares they voted on this item FOR (65,555,751 for, 96 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 16,283,021 | 0 | 1 | 0 | For |
| T. Rowe Price | 12,088,585 | 0 | 0 | 0 | For |
| Fidelity | 11,423,245 | 0 | 0 | 0 | For |
| BlackRock | 8,039,816 | 0 | 0 | 0 | For |
| Capital Group | 2,351,843 | 0 | 0 | 0 | For |
| State Street | 1,951,905 | 96 | 0 | 0 | For |
| Jackson National | 1,888,383 | 0 | 0 | 0 | For |
| Charles Schwab | 1,381,375 | 0 | 0 | 0 | For |
| Federated Hermes | 698,221 | 0 | 0 | 0 | For |
| Principal | 546,147 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 484,644 | 0 | 0 | 0 | For |
| Voya | 472,562 | 0 | 0 | 0 | For |
| JPMorgan | 469,912 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 408,465 | 0 | 0 | 0 | For |
| Equitable | 405,573 | 0 | 0 | 0 | For |
| John Hancock | 366,389 | 0 | 0 | 0 | For |
| American Century | 339,530 | 0 | 0 | 0 | For |
| MFS | 305,698 | 0 | 0 | 0 | For |
| Goldman Sachs | 281,731 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 256,383 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 255,713 | 0 | 0 | 0 | For |
| TIAA | 241,442 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 228,990 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 225,640 | 0 | 0 | 0 | For |
| Brighthouse | 195,741 | 0 | 28,784 | 0 | For |
Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.
Ranked by the number of Cytokinetics, Incorporated shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 124,432,565 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 24.50% |
| 2 | Fidelity | 17.21% |
| 3 | Vanguard | 13.89% |
| 4 | BlackRock | 9.69% |
| 5 | Wellington | 5.39% |
| 6 | State Street | 3.92% |
| 7 | Capital Group | 3.17% |
| 8 | Polar Capital Holdings Plc | 2.48% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.25% |
| 10 | Charles Schwab | 2.23% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 13.30% | 13F |
| Entities affiliated with BlackRock, Inc. | 12.26% | DEF14A |
| Entities affiliated with Fidelity Investments | 10.53% | DEF14A |
| Vanguard Group | 9.68% | 13F |
| FMR (Fidelity) | 8.62% | 13F |
| Wellington Management | 6.44% | 13F |
| Entities affiliated with Wellington Management Group LLP | 5.25% | DEF14A |
| State Street | 4.62% | 13F |
| Goldman Sachs | 1.97% | 13F |
| Robert I. Blum | 1.32% | DEF14A |
Percentages above are of 124,432,565 shares outstanding, as reported by Cytokinetics, Incorporated on its Form 10-Q dated 2026-05-04 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Cytokinetics, Incorporated’s 10-Q dated 2026-05-04. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Cytokinetics, Incorporated's shareholder meeting held 2026-05-27, in the 2025-2026 proxy season, 414 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 3,506 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Cytokinetics, Incorporated's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-27.
Cytokinetics, Incorporated proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).